ospemifene 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antiestrogens or estrogen receptor modulators, clomifene and tamoxifen derivatives	4749	128607-22-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: osphena FC-1271a ospemifene senshio	an estrogen agonist/antagonist with tissue selective effects, its biological actions are mediated through binding to estrogen receptors, this binding results in activation of estrogenic pathways in some tissues (agonism) and blockade of estrogenic pathways in others (antagonism) Molecular weight: 378.90 Formula: C24H23ClO2 CLOGP: 5.56 LIPINSKI: 1 HAC: 2 HDO: 1 TPSA: 29.46 ALOGS: -5.86 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

osphena
FC-1271a
ospemifene
senshio

an estrogen agonist/antagonist with tissue selective effects, its biological actions are mediated through binding to estrogen receptors, this binding results in activation of estrogenic pathways in some tissues (agonism) and blockade of estrogenic pathways in others (antagonism)

Molecular weight: 378.90
Formula: C24H23ClO2
CLOGP: 5.56
LIPINSKI: 1
HAC: 2
HDO: 1
TPSA: 29.46
ALOGS: -5.86
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
fu (Fraction unbound in plasma)	0 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

Date	Agency	Company	Orphan
Nov. 20, 2014	EMA	Shionogi Limited
Feb. 26, 2013	FDA	SHIONOGI INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hot flush	296.40	37.17	87	1289	51072	63436574
Vaginal discharge	183.56	37.17	42	1334	9156	63478490
Labelled drug-drug interaction medication error	182.97	37.17	45	1331	13354	63474292
No adverse event	121.05	37.17	42	1334	41363	63446283
Vaginal haemorrhage	121.02	37.17	38	1338	27449	63460197
Muscle spasms	108.41	37.17	57	1319	156093	63331553
Therapeutic response unexpected	99.76	37.17	30	1346	18729	63468917
Vulvovaginal burning sensation	72.03	37.17	15	1361	2094	63485552
Vulvovaginal discomfort	64.59	37.17	14	1362	2364	63485282
Inability to afford medication	59.18	37.17	13	1363	2334	63485312
Off label use	55.40	37.17	70	1306	674392	62813254
Vulvovaginal pruritus	49.80	37.17	12	1364	3231	63484415
Hyperhidrosis	49.19	37.17	30	1346	107806	63379840
Labelled drug-disease interaction medication error	39.14	37.17	6	1370	144	63487502

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hot flush	233.23	42.21	65	938	54812	79688573
Vaginal discharge	137.78	42.21	29	974	7434	79735951
Labelled drug-drug interaction medication error	104.51	42.21	30	973	27620	79715765
Vaginal haemorrhage	97.54	42.21	27	976	21790	79721595
Muscle spasms	93.99	42.21	45	958	174685	79568700
Therapeutic response unexpected	76.91	42.21	22	981	19924	79723461
No adverse event	63.42	42.21	22	981	37170	79706215
Vulvovaginal discomfort	63.12	42.21	12	991	1826	79741559
Vulvovaginal burning sensation	52.05	42.21	10	993	1607	79741778
Off label use	45.51	42.21	56	947	907159	78836226

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G03XC05	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Selective estrogen receptor modulators
FDA MoA	N0000000168	Selective Estrogen Receptor Modulators
FDA EPC	N0000175826	Estrogen Agonist/Antagonist
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:67079	anti-inflammatory agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Dyspareunia	indication	71315007
Atrophic vulva	indication	248861000	DOID:14275

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
60MG	OSPHENA	DUCHESNAY	N203505	Feb. 26, 2013	RX	TABLET	ORAL	8470890	Feb. 13, 2024	TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
60MG	OSPHENA	DUCHESNAY	N203505	Feb. 26, 2013	RX	TABLET	ORAL	8470890	Feb. 13, 2024	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
60MG	OSPHENA	DUCHESNAY	N203505	Feb. 26, 2013	RX	TABLET	ORAL	8470890	Feb. 13, 2024	TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE
60MG	OSPHENA	DUCHESNAY	N203505	Feb. 26, 2013	RX	TABLET	ORAL	8772353	Feb. 13, 2024	TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
60MG	OSPHENA	DUCHESNAY	N203505	Feb. 26, 2013	RX	TABLET	ORAL	8772353	Feb. 13, 2024	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
60MG	OSPHENA	DUCHESNAY	N203505	Feb. 26, 2013	RX	TABLET	ORAL	8772353	Feb. 13, 2024	TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE
60MG	OSPHENA	DUCHESNAY	N203505	Feb. 26, 2013	RX	TABLET	ORAL	9241915	Feb. 13, 2024	TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
60MG	OSPHENA	DUCHESNAY	N203505	Feb. 26, 2013	RX	TABLET	ORAL	9241915	Feb. 13, 2024	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
60MG	OSPHENA	DUCHESNAY	N203505	Feb. 26, 2013	RX	TABLET	ORAL	9241915	Feb. 13, 2024	TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE
60MG	OSPHENA	DUCHESNAY	N203505	Feb. 26, 2013	RX	TABLET	ORAL	9855224	Feb. 13, 2024	TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
60MG	OSPHENA	DUCHESNAY	N203505	Feb. 26, 2013	RX	TABLET	ORAL	9855224	Feb. 13, 2024	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
60MG	OSPHENA	DUCHESNAY	N203505	Feb. 26, 2013	RX	TABLET	ORAL	9855224	Feb. 13, 2024	TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE
60MG	OSPHENA	DUCHESNAY	N203505	Feb. 26, 2013	RX	TABLET	ORAL	6245819	July 21, 2025	TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
60MG	OSPHENA	DUCHESNAY	N203505	Feb. 26, 2013	RX	TABLET	ORAL	6245819	July 21, 2025	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
60MG	OSPHENA	DUCHESNAY	N203505	Feb. 26, 2013	RX	TABLET	ORAL	8236861	Aug. 11, 2026	TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
60MG	OSPHENA	DUCHESNAY	N203505	Feb. 26, 2013	RX	TABLET	ORAL	8236861	Aug. 11, 2026	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
60MG	OSPHENA	DUCHESNAY	N203505	Feb. 26, 2013	RX	TABLET	ORAL	8236861	Aug. 11, 2026	TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Estrogen receptor	Nuclear hormone receptor	P03372	ESR1_HUMAN	MODULATOR	IC50	6.08		WOMBAT-PK	CHEMBL
Estrogen receptor beta	Nuclear hormone receptor	Q92731	ESR2_HUMAN	ANTAGONIST	Ki	6.39		IUPHAR

External reference:

ID	Source
D08958	KEGG_DRUG
4032347	VANDF
CHEBI:73275	CHEBI
CHEMBL2105395	ChEMBL_ID
C119141	MESH_SUPPLEMENTAL_RECORD_UI
7349	IUPHAR_LIGAND_ID
7859	INN_ID
DB04938	DRUGBANK_ID
B0P231ILBK	UNII
1370971	RXNORM
199207	MMSL
29311	MMSL
d08070	MMSL
014918	NDDF
716223004	SNOMEDCT_US
C1313616	UMLSCUI
3036505	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Osphena	HUMAN PRESCRIPTION DRUG LABEL	1	55494-580	TABLET, FILM COATED	60 mg	ORAL	NDA	28 sections
Osphena	HUMAN PRESCRIPTION DRUG LABEL	1	59630-580	TABLET, FILM COATED	60 mg	ORAL	NDA	29 sections
Osphena	HUMAN PRESCRIPTION DRUG LABEL	1	59630-580	TABLET, FILM COATED	60 mg	ORAL	NDA	29 sections
Osphena	HUMAN PRESCRIPTION DRUG LABEL	1	59630-580	TABLET, FILM COATED	60 mg	ORAL	NDA	29 sections
Osphena	HUMAN PRESCRIPTION DRUG LABEL	1	75929-178	TABLET, FILM COATED	60 mg	ORAL	NDA	29 sections